Investor updates Suchbegriff Suchen Löschen 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Published on: 19 April 2018 Reminder: Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call Roche will publish its Sales Results for the 1st Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Thursday April 26th, 2018. mehr Published on: 18 April 2018 Launch of Tecentriq in 2L+ NSCLC in Japan mehr Published on: 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra® (emicizumab-kxwh) for people with haemophilia A without factor VIII ... mehr Published on: 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Roche announced today that new data on its approved and investigational medicines for neurological conditions will be presented during the 70th American Academy of Neurology (AAN) Annual Meeting from ... mehr Published on: 14 April 2018 Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting Roche today announced that it will present data from across its broad cancer immunotherapy development programme, including approved and investigational medicines, during the American Association for ... mehr Published on: 6 April 2018 Roche completes acquisition of Flatiron Health Roche today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a ... mehr Published on: 28 März 2018 Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation Roche today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co., Ltd, a member of the Roche Group, in the patent litigation case relating to Hemlibra® ... mehr Published on: 27 März 2018 Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call Roche will publish its Sales Results for the 1st Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Thursday April 26th, 2018. mehr Published on: 26 März 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the ... mehr Published on: 22 März 2018 FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to ... mehr Published on: 20 März 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus ... mehr Published on: 14 März 2018 Save the date: Roche Analyst Event at ASCO 2018 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... mehr Published on: 13 März 2018 Roche Generalversammlung 2018 Roche gab heute bekannt, dass ihre ordentliche Generalversammlung allen Anträgen des Verwaltungsrates zugestimmt hat. mehr Published on: 8 März 2018 Wechsel in der erweiterten Konzernleitung von Roche Roche hat heute bekannt gegeben, dass John C. Reed (1958), M.D., Ph.D., seit 2013 Leiter von Roche Pharma Forschung und frühe Entwicklung (pRED), sich entschieden hat, das Unternehmen aus ... mehr Published on: 27 Februar 2018 European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors Roche today announced that the European Commission has approved Hemlibra® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. mehr Published on: 15 Februar 2018 Roche übernimmt Flatiron Health, um die branchenweite Entwicklung und Bereitstellung von bahnbrechenden Medikamenten für Krebspatienten zu beschleunigen Roche und Flatiron Health, Inc. gaben heute bekannt, dass die beiden Partner eine definitive Vereinbarung unterzeichnet haben, nach der Roche alle Aktien von Flatiron Health übernehmen wird. Bislang ... mehr Published on: 14 Februar 2018 FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris Roche announced today that the US Food and Drug Administration (FDA) has accepted the company’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of ... mehr Published on: 12 Februar 2018 Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema Roche today announced encouraging results from the Phase II BOULEVARD study. mehr Published on: 8 Februar 2018 Roche purchases shares in tender offer for Ignyta, Inc. Roche and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its ... mehr Published on: 6 Februar 2018 Reminder: Invitation to Roche's Virtual Pipeline Event We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. mehr Published on: 6 Februar 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell ... mehr Published on: 1 Februar 2018 Roche reports good results in 2017 Commenting on the Group’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am ... mehr Published on: 29 Januar 2018 FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder Roche announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its investigational oral medicine balovaptan (previously known as RG7314), a ... mehr Published on: 26 Januar 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra® (emicizumab) for routine prophylaxis of bleeding episodes in ... mehr Published on: 26 Januar 2018 Invitation to Roche's Virtual Pipeline Event We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. mehr Published on: 24 Januar 2018 Reminder: Invitation to Roche's Full Year Results 2017 Presentation Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. mehr Published on: 19 Januar 2018 TECENTRIQ approved in Japan for the treatment of unresectable, advanced or recurrent NSCLC mehr Published on: 12 Januar 2018 OCREVUS (Ocrelizumab) von Roche erhält Zulassung in der Europäischen Union für schubförmige multiple Sklerose und primär progrediente multiple Sklerose Wie Roche heute bekannt gab, hat die Europäische Kommission die Zulassung von OCREVUS® (Ocrelizumab) für folgende Patientengruppen erteilt: Patienten mit aktiver schubförmiger multipler Sklerose, die ... mehr Published on: 10 Januar 2018 Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta, Inc. at a price of US$ 27.00 per share. mehr Published on: 8 Januar 2018 Invitation to Roche's Full Year Results 2017 Presentation Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. mehr Published on: 8 Januar 2018 Roche und GE gehen eine Partnerschaft zur Entwicklung einer integrierten digitalen Diagnoseplattform ein, um die Behandlung von Krebs- und Intensivpatienten zu optimieren Roche hat heute bekanntgegeben, eine strategische, langfristige Partnerschaft mit GE Healthcare eingegangen zu sein, um gemeinsam digitale Lösungen zur klinischen Entscheidungsunterstützung zu ... mehr Published on: 4 Januar 2018 Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas Roche announced today the launch of the cobas® Plasma Separation Card. This new solution is a stable and easy-to-use sample collection device for HIV plasma viral load testing. By providing a small ... mehr
Published on: 19 April 2018 Reminder: Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call Roche will publish its Sales Results for the 1st Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Thursday April 26th, 2018. mehr
Published on: 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra® (emicizumab-kxwh) for people with haemophilia A without factor VIII ... mehr
Published on: 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Roche announced today that new data on its approved and investigational medicines for neurological conditions will be presented during the 70th American Academy of Neurology (AAN) Annual Meeting from ... mehr
Published on: 14 April 2018 Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting Roche today announced that it will present data from across its broad cancer immunotherapy development programme, including approved and investigational medicines, during the American Association for ... mehr
Published on: 6 April 2018 Roche completes acquisition of Flatiron Health Roche today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a ... mehr
Published on: 28 März 2018 Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation Roche today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co., Ltd, a member of the Roche Group, in the patent litigation case relating to Hemlibra® ... mehr
Published on: 27 März 2018 Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call Roche will publish its Sales Results for the 1st Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Thursday April 26th, 2018. mehr
Published on: 26 März 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the ... mehr
Published on: 22 März 2018 FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to ... mehr
Published on: 20 März 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus ... mehr
Published on: 14 März 2018 Save the date: Roche Analyst Event at ASCO 2018 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... mehr
Published on: 13 März 2018 Roche Generalversammlung 2018 Roche gab heute bekannt, dass ihre ordentliche Generalversammlung allen Anträgen des Verwaltungsrates zugestimmt hat. mehr
Published on: 8 März 2018 Wechsel in der erweiterten Konzernleitung von Roche Roche hat heute bekannt gegeben, dass John C. Reed (1958), M.D., Ph.D., seit 2013 Leiter von Roche Pharma Forschung und frühe Entwicklung (pRED), sich entschieden hat, das Unternehmen aus ... mehr
Published on: 27 Februar 2018 European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors Roche today announced that the European Commission has approved Hemlibra® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. mehr
Published on: 15 Februar 2018 Roche übernimmt Flatiron Health, um die branchenweite Entwicklung und Bereitstellung von bahnbrechenden Medikamenten für Krebspatienten zu beschleunigen Roche und Flatiron Health, Inc. gaben heute bekannt, dass die beiden Partner eine definitive Vereinbarung unterzeichnet haben, nach der Roche alle Aktien von Flatiron Health übernehmen wird. Bislang ... mehr
Published on: 14 Februar 2018 FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris Roche announced today that the US Food and Drug Administration (FDA) has accepted the company’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of ... mehr
Published on: 12 Februar 2018 Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema Roche today announced encouraging results from the Phase II BOULEVARD study. mehr
Published on: 8 Februar 2018 Roche purchases shares in tender offer for Ignyta, Inc. Roche and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its ... mehr
Published on: 6 Februar 2018 Reminder: Invitation to Roche's Virtual Pipeline Event We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. mehr
Published on: 6 Februar 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell ... mehr
Published on: 1 Februar 2018 Roche reports good results in 2017 Commenting on the Group’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am ... mehr
Published on: 29 Januar 2018 FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder Roche announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its investigational oral medicine balovaptan (previously known as RG7314), a ... mehr
Published on: 26 Januar 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra® (emicizumab) for routine prophylaxis of bleeding episodes in ... mehr
Published on: 26 Januar 2018 Invitation to Roche's Virtual Pipeline Event We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. mehr
Published on: 24 Januar 2018 Reminder: Invitation to Roche's Full Year Results 2017 Presentation Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. mehr
Published on: 19 Januar 2018 TECENTRIQ approved in Japan for the treatment of unresectable, advanced or recurrent NSCLC mehr
Published on: 12 Januar 2018 OCREVUS (Ocrelizumab) von Roche erhält Zulassung in der Europäischen Union für schubförmige multiple Sklerose und primär progrediente multiple Sklerose Wie Roche heute bekannt gab, hat die Europäische Kommission die Zulassung von OCREVUS® (Ocrelizumab) für folgende Patientengruppen erteilt: Patienten mit aktiver schubförmiger multipler Sklerose, die ... mehr
Published on: 10 Januar 2018 Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta, Inc. at a price of US$ 27.00 per share. mehr
Published on: 8 Januar 2018 Invitation to Roche's Full Year Results 2017 Presentation Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. mehr
Published on: 8 Januar 2018 Roche und GE gehen eine Partnerschaft zur Entwicklung einer integrierten digitalen Diagnoseplattform ein, um die Behandlung von Krebs- und Intensivpatienten zu optimieren Roche hat heute bekanntgegeben, eine strategische, langfristige Partnerschaft mit GE Healthcare eingegangen zu sein, um gemeinsam digitale Lösungen zur klinischen Entscheidungsunterstützung zu ... mehr
Published on: 4 Januar 2018 Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas Roche announced today the launch of the cobas® Plasma Separation Card. This new solution is a stable and easy-to-use sample collection device for HIV plasma viral load testing. By providing a small ... mehr